Stratos Wealth Advisors LLC Purchases 20,628 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Stratos Wealth Advisors LLC raised its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 21.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 117,721 shares of the biopharmaceutical company’s stock after buying an additional 20,628 shares during the quarter. Stratos Wealth Advisors LLC owned about 0.10% of Catalyst Pharmaceuticals worth $2,748,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CPRX. Rothschild Investment LLC raised its stake in shares of Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,520 shares in the last quarter. Advisory Services Network LLC acquired a new stake in Catalyst Pharmaceuticals in the third quarter valued at approximately $39,000. Quarry LP acquired a new stake in Catalyst Pharmaceuticals in the third quarter valued at approximately $40,000. Financial Life Planners purchased a new position in Catalyst Pharmaceuticals in the third quarter worth $42,000. Finally, Bessemer Group Inc. grew its holdings in Catalyst Pharmaceuticals by 331.4% in the third quarter. Bessemer Group Inc. now owns 3,486 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 2,678 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CPRX. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday, March 27th. Citigroup boosted their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Three research analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Strong Buy” and an average price target of $34.00.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock opened at $24.69 on Friday. The firm’s 50 day simple moving average is $24.10 and its two-hundred day simple moving average is $22.86. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 0.72 and a beta of 0.67. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $26.58.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).